Evidence map›Paper›PMID 35675744›Full record

ArticleMultiple sclerosis and related disorders2022

A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis.

Marta Ponzano, Irene Schiavetti, Francesca Bovis, Doriana Landi, Luca Carmisciano, Nicola De Rossi, Cinzia Cordioli, Lucia Moiola, Marta Radaelli, Paolo Immovilli and 24 more

Open access · bronzeAbstract read
In one paragraph

Article in Multiple sclerosis and related disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Monkeypox in Multiple Sclerosis patients: Should we be alert?Multiple sclerosis and related disorders · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 20 institutions in 4 countries.

Marta PonzanoDepartment of Health Sciences, University of Genoa, Genoa, Italy. Electronic address: ponzano.marta@gmail.com.
Irene SchiavettiDepartment of Health Sciences, University of Genoa, Genoa, Italy.
Francesca BovisDepartment of Health Sciences, University of Genoa, Genoa, Italy.
Doriana LandiMultiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy.
Luca CarmiscianoDepartment of Health Sciences, University of Genoa, Genoa, Italy.
Nicola De RossiCentro Sclerosi Multipla ASST Spedali Civili di Brescia, Montichiari, Italy.
Cinzia CordioliCentro Sclerosi Multipla ASST Spedali Civili di Brescia, Montichiari, Italy.
Lucia MoiolaDepartment of Neurology, Multiple Sclerosis Center, IRCCS Ospedale San Raffaele, Milan, Italy.
Marta RadaelliDepartment of Neurology and Multiple Sclerosis Center, ASST "Papa Giovanni XXIII", Bergamo, Italy.
Paolo ImmovilliMultiple Sclerosis Center, Ospedale Guglielmo da Saliceto, Piacenza, Italy.
Marco CapobiancoRegional Referral Multiple Sclerosis Centre, Department of Neurology, University Hospital San Luigi, Orbassano, Torino, Italy.
Margherita Monti BragadinAISM Rehabilitation Center, Italian MS Society, Genoa, Italy.
Eleonora CoccoCentro Sclerosi Multipla, ATS Sardegna, Cagliari, Italy.
Cinzia ScandellariIRCCS Istituto delle Scienze Neurologiche di Bologna, UOSI Riabilitazione Sclerosi Multipla, Bologna, Italy.
Paola CavallaMS Center, Department of Neuroscience, City of Health and Science University Hospital of Turin, Turin, Italy.
Ilaria PesciCentro SM UOC Neurologia, Fidenza, AUSL PR, Fidenza, Italy.
Paolo ConfalonieriMultiple Sclerosis Centre, Neuroimmunology Department 'Carlo Besta' Neurological Institute, Milan, Italy.
Paola PeriniDepartment of Neurology Multiple Sclerosis Center, University of Padua, Padova, Italy.
Roberto BergamaschiMultiple Sclerosis Research Center, IRCCS Mondino Foundation, Pavia, Italy.
Matilde IngleseDepartment of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Maria PetraccaDepartment of Neurosciences and Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy; Department of Human Neurosciences, Sapienza University, Rome, Italy.
Maria TrojanoDepartment of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.
Gioacchino TedeschiDepartment of Advanced Medical and Surgical Sciences, University of Campania "L. Vanvitelli", Naples, Italy.
Giancarlo ComiInstitute of Experimental Neurology, IRCCS Ospedale San Raffaele, Milano.
Mario Alberto BattagliaResearch Department, Italian Multiple Sclerosis Foundation, Genoa, Italy; Department of Life Sciences, University of Siena, Italy.
Francesco PattiDepartment of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania; Centro Sclerosi Multipla, Policlinico Catania, University of Catania.
Yara Dadalti FragosoPost Graduate Studies, Universidade Metropolitana de Santos, Santos, SP, Brazil.
Sedat SenOndokuz Mayis University School of Medicine Samsun, Turkey.
Aksel SivaIstanbul University Cerrahpasa School of Medicine Istanbul, Turkey.
Rana KarabudakHacettepe University School of Medicine Ankara, Turkey.
Husnu EfendiKocaeli University School of Medicine Kocaeli, Turkey.
Roberto FurlanDivision of Neuroscience, Italian Neuroimmunology Association-AINI, IRCCS Ospedale San Raffaele, Institute of Experimental Neurology, Milano, Italy.
Marco SalvettiDepartment of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy; Unit of Neurology, IRCCS Neuromed, Pozzilli, Isernia, Italy.
Maria Pia SormaniDepartment of Health Sciences, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
University of Genoa · ITIRCCS Ospedale San Raffaele · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITOspedale Policlinico San Martino · ITAssociazione Italiana Sclerosi Multipla · ITATS Sardegna (Italy) · ITFederico II University Hospital · ITFondazione IRCCS Istituto Neurologico Carlo Besta · ITGuglielmo da Saliceto Hospital · ITHacettepe University · TRIstanbul University-Cerrahpaşa · TRIstituto delle Scienze Neurologiche di Bologna · ITIstituto Neurologico Mediterraneo · ITKocaeli Üniversitesi · TROndokuz Mayıs University · TROspedale Papa Giovanni XXIII · ITOspedale San Luigi Gonzaga · ITUniversidade Metropolitana de Santos · BRUniversity of Bari Aldo Moro · ITUniversity of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany risk factors for the development of severe forms of Covid-19 have been identified, some applying to the general population and others specific to Multiple Sclerosis (MS) patients. However, a score for quantifying the individual risk of severe Covid-19 in patients with MS is not available. The aim of this study was to construct such score and to evaluate its performance.

methodsData on patients with MS infected with Covid-19 in Italy, Turkey and South America were extracted from the Musc-19 platform. After imputation of missing values, data were separated into training data set (70%) and validation data set (30%). Univariable logistic regression models were performed in the training dataset to identify the main risk factors to be included in the multivariable logistic regression analyses. To select the most relevant variables we applied three different approaches: (1) multivariable stepwise, (2) Lasso regression, (3) Bayesian model averaging. Three scores were defined as the linear combination of the coefficients estimated in the models multiplied by the corresponding value of the variables and higher scores were associated to higher risk of severe Covid-19 course. The performances of the three scores were compared in the validation dataset based on the area under the ROC curve (AUC) and an optimal cut-off was calculated in the training dataset for the score with the best performance. The probability of showing a severe Covid-19 course was calculated based on the score with the best performance.

results3852 patients were included in the study (2696 in the training dataset and 1156 in the validation data set). 17% of the patients required hospitalization and risk factors for severe Covid-19 course were older age, male sex, living in Turkey or South America instead of living in Italy, presence of comorbidities, progressive MS, longer disease duration, higher Expanded Disability Status Scale, Methylprednisolone use and anti-CD20 treatment. The score with the best performance was the one derived using the Lasso selection approach (AUC= 0.72) and it was built with the following variables: age, sex, country, BMI, presence of comorbidities, EDSS, methylprednisolone use, treatment. An excel spreadsheet to calculate the score and the probability of severe Covid-19 is available at the following link: https://osf.io/ac47u/?view_only=691814d57b564a34b3596e4fcdcf8580.

conclusionsThe originality of this study consists in building a useful tool to quantify the individual risk for Covid-19 severity based on patient's characteristics. Due to the modest predictive ability and to the need of external validation, this tool is not ready for being fully used in clinical practice to make important decisions or interventions. However, it can be used as an additional instrument to identify high-risk patients and persuade them to take important measures to prevent Covid-19 infection (i.e. getting vaccinated against Covid-19, adhering to social distancing, and using of personal protection equipment).

Indexed as

COVID-19Multiple SclerosisBayes TheoremHumansMaleMethylprednisolonePersonal Protective EquipmentMethylprednisoloneCovid-19 severityMultiple SclerosisRisk assessment score

Identifiers

PMID35675744
PMCPMC9130313
OpenAlexW4281476562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.